vs
AdvanSix Inc.（ASIX）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是REPLIGEN CORP的1.8倍（$359.9M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -0.8%，领先7.5%），REPLIGEN CORP同比增速更快（13.6% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ASIX vs RGEN — 直观对比
营收规模更大
ASIX
是对方的1.8倍
$197.9M
营收增速更快
RGEN
高出4.3%
9.4%
净利率更高
RGEN
高出7.5%
-0.8%
自由现金流更多
ASIX
多$18.6M
$17.6M
两年增速更快
RGEN
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $197.9M |
| 净利润 | $-2.8M | $13.3M |
| 毛利率 | 7.6% | 52.5% |
| 营业利润率 | -0.7% | 9.0% |
| 净利率 | -0.8% | 6.7% |
| 营收同比 | 9.4% | 13.6% |
| 净利润同比 | -892.9% | 143.9% |
| 每股收益（稀释后） | $-0.11 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXRGEN
| Q4 25 | $359.9M | $197.9M | ||
| Q3 25 | $374.5M | $188.8M | ||
| Q2 25 | $410.0M | $182.4M | ||
| Q1 25 | $377.8M | $169.2M | ||
| Q4 24 | $329.1M | $174.1M | ||
| Q3 24 | $398.2M | $154.9M | ||
| Q2 24 | $453.5M | $154.1M | ||
| Q1 24 | $336.8M | $151.3M |
净利润ASIXRGEN
| Q4 25 | $-2.8M | $13.3M | ||
| Q3 25 | $-2.6M | $14.9M | ||
| Q2 25 | $31.4M | $14.9M | ||
| Q1 25 | $23.3M | $5.8M | ||
| Q4 24 | $352.0K | $-30.3M | ||
| Q3 24 | $22.3M | $-654.0K | ||
| Q2 24 | $38.9M | $3.3M | ||
| Q1 24 | $-17.4M | $2.1M |
毛利率ASIXRGEN
| Q4 25 | 7.6% | 52.5% | ||
| Q3 25 | 6.8% | 53.2% | ||
| Q2 25 | 14.3% | 50.0% | ||
| Q1 25 | 14.2% | 53.6% | ||
| Q4 24 | 3.4% | 26.1% | ||
| Q3 24 | 14.4% | 50.0% | ||
| Q2 24 | 17.9% | 49.8% | ||
| Q1 24 | 0.9% | 49.5% |
营业利润率ASIXRGEN
| Q4 25 | -0.7% | 9.0% | ||
| Q3 25 | -0.9% | 8.9% | ||
| Q2 25 | 7.7% | 7.6% | ||
| Q1 25 | 7.7% | 3.9% | ||
| Q4 24 | -3.9% | -17.7% | ||
| Q3 24 | 7.5% | -5.1% | ||
| Q2 24 | 11.5% | 1.0% | ||
| Q1 24 | -7.0% | 1.3% |
净利率ASIXRGEN
| Q4 25 | -0.8% | 6.7% | ||
| Q3 25 | -0.7% | 7.9% | ||
| Q2 25 | 7.7% | 8.2% | ||
| Q1 25 | 6.2% | 3.4% | ||
| Q4 24 | 0.1% | -17.4% | ||
| Q3 24 | 5.6% | -0.4% | ||
| Q2 24 | 8.6% | 2.2% | ||
| Q1 24 | -5.2% | 1.4% |
每股收益（稀释后）ASIXRGEN
| Q4 25 | $-0.11 | $0.24 | ||
| Q3 25 | $-0.10 | $0.26 | ||
| Q2 25 | $1.15 | $0.26 | ||
| Q1 25 | $0.86 | $0.10 | ||
| Q4 24 | $0.02 | $-0.55 | ||
| Q3 24 | $0.82 | $-0.01 | ||
| Q2 24 | $1.43 | $0.06 | ||
| Q1 24 | $-0.65 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $815.2M | $2.1B |
| 总资产 | $1.7B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ASIXRGEN
| Q4 25 | $19.8M | $767.6M | ||
| Q3 25 | $23.7M | $748.7M | ||
| Q2 25 | $18.4M | $708.9M | ||
| Q1 25 | $8.3M | $697.2M | ||
| Q4 24 | $19.6M | $757.4M | ||
| Q3 24 | $17.3M | $784.0M | ||
| Q2 24 | $12.1M | $809.1M | ||
| Q1 24 | $20.6M | $780.6M |
总债务ASIXRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASIXRGEN
| Q4 25 | $815.2M | $2.1B | ||
| Q3 25 | $818.2M | $2.1B | ||
| Q2 25 | $823.7M | $2.1B | ||
| Q1 25 | $794.4M | $2.0B | ||
| Q4 24 | $774.6M | $2.0B | ||
| Q3 24 | $766.4M | $2.0B | ||
| Q2 24 | $746.6M | $2.0B | ||
| Q1 24 | $713.2M | $2.0B |
总资产ASIXRGEN
| Q4 25 | $1.7B | $2.9B | ||
| Q3 25 | $1.7B | $2.9B | ||
| Q2 25 | $1.6B | $2.9B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.9B | ||
| Q1 24 | $1.5B | $2.8B |
负债/权益比ASIXRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $17.6M |
| 自由现金流率自由现金流/营收 | 10.0% | 8.9% |
| 资本支出强度资本支出/营收 | 7.7% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $6.4M | $93.9M |
8季度趋势，按日历期对齐
经营现金流ASIXRGEN
| Q4 25 | $63.7M | $25.7M | ||
| Q3 25 | $26.6M | $48.1M | ||
| Q2 25 | $21.1M | $28.6M | ||
| Q1 25 | $11.4M | $15.0M | ||
| Q4 24 | $64.2M | $39.2M | ||
| Q3 24 | $57.3M | $49.3M | ||
| Q2 24 | $50.2M | $42.2M | ||
| Q1 24 | $-36.2M | $44.7M |
自由现金流ASIXRGEN
| Q4 25 | $36.1M | $17.6M | ||
| Q3 25 | $66.0K | $43.4M | ||
| Q2 25 | $-7.2M | $21.5M | ||
| Q1 25 | $-22.6M | $11.4M | ||
| Q4 24 | $29.8M | $33.6M | ||
| Q3 24 | $26.8M | $42.3M | ||
| Q2 24 | $16.7M | $37.4M | ||
| Q1 24 | $-71.6M | $36.4M |
自由现金流率ASIXRGEN
| Q4 25 | 10.0% | 8.9% | ||
| Q3 25 | 0.0% | 23.0% | ||
| Q2 25 | -1.7% | 11.8% | ||
| Q1 25 | -6.0% | 6.8% | ||
| Q4 24 | 9.1% | 19.3% | ||
| Q3 24 | 6.7% | 27.3% | ||
| Q2 24 | 3.7% | 24.3% | ||
| Q1 24 | -21.3% | 24.0% |
资本支出强度ASIXRGEN
| Q4 25 | 7.7% | 4.1% | ||
| Q3 25 | 7.1% | 2.5% | ||
| Q2 25 | 6.9% | 3.9% | ||
| Q1 25 | 9.0% | 2.1% | ||
| Q4 24 | 10.4% | 3.2% | ||
| Q3 24 | 7.7% | 4.5% | ||
| Q2 24 | 7.4% | 3.1% | ||
| Q1 24 | 10.5% | 5.5% |
现金转化率ASIXRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | 0.67× | 1.92× | ||
| Q1 25 | 0.49× | 2.57× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
RGEN
暂无分部数据
